Adherium Ltd (ASX: ADR) Share Price and News

He is chair of Risk Committee.

Mr Cook is an investor in the Australian life science sector. He was formerly head of the life science private equity team at Rothschild Asset Management in the UK. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook is experienced in creating value in emerging biotech enterprises, through participation with management. He has served on over 40 boards in roles, including chair of private and public biotechnology companies listed on NASDAQ, AMEX, LSE, TSX and ASX. He is currently Managing Director of BioScience Managers (manager of a major shareholder in Adherium), and sits on the board of Avita Medical, Rex Bionics Pty Ltd, Humanetix Ltd, Marine Department Ltd, Cambridge Respiratory Innovations Ltd, and Sea Dragon Ltd. He has held no other Australian public company directorships in the last three years. As noted, Mr Curnock Cook has an association with shareholders through his capacity as Managing Director of BioScience Managers Pty Ltd.

Mr Baran has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a shareholder. In addition to his role at Trudell, Mr Baran is an investor in and Director of several medical device and e-health/ connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. Mr Baran has been responsible for the marketing of new drug delivery technologies to medical opinion leaders and pharmaceutical companies. This has included collaboration with business and clinical partners in the design and co-ordination of clinical studies. He has also been granted several US and international patents for medical devices for drug delivery and minimally invasive surgery. Mr Baran currently serves on the Advisory Board of the Lawrence National Centre for Policy and Management.

Mr Gessner has more than 25 years experience serving in leadership roles for Pfizer, Teva, AstraZeneca and GlaxoSmithKline (GSK). He brings experience in leading digital health transformation in global respiratory health markets. In particular, he is experienced in market access, product launch strategy and leveraging the very latest applications of AI in healthcare.

Ms Durrans joined BioScience Managers in 2017 after moving to Melbourne from the UK. She is a Partner in the investment team. Ms Durrans began her career founding a commercial relocation business before joining CRSI Ltd, a start-up boutique consulting firm advising early-stage, investor backed technology companies on issues relating to rapid growth and global commercialisation. She specialises in shaping boards and management teams that underpin growth, execution, and long term value creation.

-

-

-

-

-

-